Treatment Information

Back

Melanoma treatment details. Biologic therapy.

Yale University School of Medicine, New Haven, Connecticut, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New Haven, Connecticut
Treatments:Biologic therapyHospital:Yale University School of Medicine
Drugs:Journal:Link
Date:May 2011

Description:

Patients:
This study involved 39 melanoma patients who had not previously received chemotherapy. The average patient age was 64 years and 67% were male.

Treatment:
Patients were treated with the biologic therapy agent called dasatinib, which is an inhibitor of src kinases and causes reduced melanoma cell growth.

Toxicities:
The most severe toxicities were of grade 4 and included shortness of breath and pleural effusion (fluid in the lungs). Grade 3 fatigue was also reported.

Results:
The median overall survival was 12.7 months.

Correspondence: Dr. Harriet M. Kluger; email: [email protected]



Back